

# Pathways to Alzheimer's disease

<https://neurodegenerationresearch.eu/survey/pathways-to-alzheimer%c2%92s-disease/>

## Principal Investigators

Henrik Zetterberg

## Institution

Göteborg University

## Contact information of lead PI Country

Sweden

## Title of project or programme

Pathways to Alzheimer's disease

## Source of funding information

The Swedish Brain Foundation

## Total sum awarded (Euro)

€ 108,814

## Start date of award

01/07/2015

## Total duration of award in years

2.5

## Keywords

### Research Abstract

Using patient materials in conjunction with cell, zebrafish and hippocampal slice models, we will address four major hypotheses of fundamental importance to the AD research field:

(i) Many patients diagnosed with clinical AD do not have AD neuropathology.  
(ii) Amyloid build-up in AD is caused by imbalance in the production and clearance of specific Abeta isoforms.

(iii) Abeta needs brain incubation over years to become toxic.

(iv) Gamma-Secretase dysfunction and/or microglial activation mediate Abeta toxicity.

The uniqueness of the project lies in the combination of well-characterised clinical materials (including cerebrospinal fluid samples [CSF; the fluid that surrounds the brain and communicates freely with the brain interstitial fluid] and brain specimens), state-of-the-art clinical

laboratory testing, groundbreaking approaches to biomarker discovery, and both novel and established animal and cell models. The proposed research is translational and involves clinical and pre-clinical units at the Sahlgrenska University Hospital and the Sahlgrenska Academy, as well as several national and international collaborators.

**Further information available at:**

**Types:**

Investments < €500k

**Member States:**

Sweden

**Diseases:**

N/A

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A